Ipsen’s R&D is recognized for its unique expertise in peptides and toxins. This research strategy is guided by the principle of service to patients to deliver therapeutic solutions for unmet medical needs.
“Dare, share, care” drive Ipsen’s R&D.
“Dare”, because our vision is based on scientific curiosity and risk-taking as we continue to innovate and push the frontiers of knowledge. To discover new targets, create innovative therapeutic treatments, and explore emerging fields, Ipsen has teamed up in unique partnerships at the very early stages of research tackling the major scientific challenges of the future. To develop new therapeutic solutions with significant clinical and patient benefits we need to explore new scientific ground and take calculated risks at each step along the way.
“Share”, because creativity feeds on multiple collaborations with both academic research and innovative companies. This tradition of collaborative efforts and partnerships is in Ipsen’s R&D DNA. The Group deploys a “win-win” approach with partners and internal teams to respond as quickly as possible to scientific and medical challenges.
“Care”, because the patient always comes first and is central to the company’s primary aims to provide patients with therapeutic solutions and define molecules with the desired efficacy and safety. Translational medicine is integrated into all R&D phases to lead the emergence of therapeutic concepts and guide the clinical research during the drug development process. The aim of precision medicine approach is to accurately identify the patient group most likely to benefit from the proposed treatment and to optimize the use of new molecules.
A long tradition of successful partnerships and alliances
Since its inception, Ipsen has consistently implemented an open Research and Development strategy to nurture its own innovation capacities. These networks are built around Ipsen’s areas of expertise in endocrinology, neurology and oncology. The goals of these partnerships are to strengthen Ipsen’s R&D innovation capacity, notably by giving access to new and promising technologies and support the exploration of new research fields.
Active clinical research
Ipsen pioneered sustained-release formulations and could be the first company in the world to offer a botulinum toxin in a ready-to- use liquid formulation. More than 20 studies were in progress or completed in 2015 and early 2016, from preclinical to phase III clinical phases. Four phase III clinical studies will start recruiting patients in 2016 to evaluate the safety and efficacy of new drugs or existing drugs in new indications. Based on the positive results from some of these trials, the Group has discovered and developed new molecules or for drugs which are already marketed, new formulations, indications, or registrations in new geographical zones.
Patient-driven research and development
Ipsen aims to limit the number of patients it recruits in early-stage studies. For each molecule, we design the best possible clinical development plan, thanks to the use of various tools such as modelling and simulation and integrated biological markers. We want to provide effective and safe therapeutic solutions for our patients who suffer from disabling diseases.